Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs);Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28

Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs);Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28

Composite Endpoint of Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 28.;Proportion of Participants Experiencing Treatment-Emergent Adverse Events

Composite Endpoint of Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 28.;Proportion of Participants Experiencing Treatment-Emergent Adverse Events

Proportion of Participants Experiencing Treatment-Emergent Adverse Events;Composite Endpoint of All-cause Medically Attended Visits (MAVs; Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28.

Proportion of Participants Experiencing Treatment-Emergent Adverse Events;Composite Endpoint of All-cause Medically Attended Visits (MAVs; Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28.

Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14.;Proportion of Participants Experiencing Treatment-Emergent Adverse Events

Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14.;Proportion of Participants Experiencing Treatment-Emergent Adverse Events